Monthly Oral Ibandronate Is Well Tolerated and Efficacious in Postmenopausal Women: Results from the Monthly Oral Pilot Study

Jean-Yves Reginster, Katie M. Wilson, Etienne Dumont, Bernard Bonvoisin, and Joanne Barrett

Unité d’Exploration du Metabolisme de l’Os et du Cartilage (J.-Y.R.), University of Liège, B-4020 Liège, Belgium; F. Hoffmann-La Roche Ltd. (K.M.W., B.B., J.B.), Basel, CH-4070, Switzerland; and GlaxoSmithKline (E.D.), Collegeville, Pennsylvania 19426

Context: Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing.

Objective: The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once-monthly oral ibandronate.

Design: A randomized, 3-month, double-blind, placebo-controlled, phase I study (Monthly Oral Pilot Study) was conducted.

Setting: The study was conducted at five clinical trial centers in the United Kingdom and Belgium.

Patients or Other Participants: Subjects were postmenopausal women (age, 55–80 yr; ≥3 yr post menopause; n = 144).

Intervention(s): Once-monthly oral ibandronate 50, 100, or 150 mg or placebo was used. After the first cycle, the 50-mg arm was split, with participants continuing on either 50 or 100 mg.

Main Outcome Measure(s): Primary outcome measures were safety, serum and urinary C-telopeptide (CTX), and serum ibandronate AUC0–91.

Results: Once-monthly oral ibandronate was well tolerated, with a similar overall and upper gastrointestinal safety profile to placebo. Once-monthly ibandronate was also highly effective in decreasing bone turnover; substantial reductions from baseline in serum CTX (∼56.7% and ∼40.7% in the 150- and 100-mg arms, respectively; P < 0.001 vs. placebo) and urinary CTX (∼54.1% and ∼34.6%, respectively; P < 0.001 vs. placebo) were observed at d 91 (30 d after the final dose). Analysis of the area under the effect curve (d 1–91) for change from baseline (percent × days) in serum CTX and urinary CTX indicated a dose-response relationship. The AUC0–91 for ibandronate increased with dose but not in a dose-proportional manner.

Conclusions: These findings indicate a potential role for once-monthly oral ibandronate in the treatment of postmenopausal osteoporosis. (J Clin Endocrinol Metab 90: 5018–5024, 2005)
nate that aims to overcome current adherence issues with oral bisphosphonates through the provision of less frequent dosing regimens, such as once monthly. Unlike other bisphosphonates, the high potency of ibandronate (25), together with its favorable tolerability profile, allow dosing with extended intervals, beyond the weekly dosing concept. A recent, randomized, double-blind, placebo-controlled, phase III, fracture-prevention study [oral ibandronate Osteoporosis vertebral fracture study in North America and Europe (BONE)] demonstrated the antifracture efficacy and safety of daily (2.5 mg) and intermittent (20 mg every other day for 12 doses, followed by more than 2 months drug-free interval every 3 months) oral ibandronate regimens in postmenopausal women with osteoporosis (26). After 3 yr, daily and intermittent oral ibandronate significantly reduced the risk of new vertebral fractures, by 62% (P = 0.0001) and 50% (P = 0.0006), respectively, relative to placebo (difference between treatments, P = 0.2785). Significant and substantial increases in BMD and decreases in biochemical markers of bone turnover were also observed. Ibandronate was well tolerated, with a similar safety profile to placebo.

In light of these findings and the beneficial effects for adherence with less frequent bisphosphonate administrations, we performed a randomized, double-blind, placebo-controlled, phase I, dose-ranging study [Monthly Oral Pilot Study (MOPS)] to establish the feasibility of once-monthly dosing with oral ibandronate in postmenopausal women, the findings of which are reported herein.

**Subjects and Methods**

**Participants**

All participants were women, 55–80 yr old, who were postmenopausal for at least 3 yr at enrollment. No specific lumbar spine BMD inclusion criteria were set. Participants were excluded from the study if they had: a dietary calcium intake less than 500 mg/d; received drugs known to affect bone metabolism within 6 months, treatment with bisphosphonates or fluoride within 12 months or for more than 2 yr, or any investigational drug within 30 d; undergone bilateral oophorectomy; or diseases or disorders known to influence bone metabolism, including chronic gastrointestinal (GI) or liver disease, malignant disease within 10 yr, diagnosed breast cancer within 20 yr, alcoholism, primary hyperparathyroidism, Paget’s disease, osteomalacia, or active thyroid disease without treatment. Participants with esophageal abnormalities, active gastric or duodenal ulcers, renal impairment, vitamin D deficiency, allergy to bisphosphonates, or serum calcium levels at least 2.6 or less than 2.0 mmol/liter were also excluded. Certain concomitant medications and supplements were allowed but had to be recorded on the case report form. All participants provided written informed consent; the study complied with the requirements of the Declaration of Helsinki and with the International Conference on Harmonization Good Clinical Practice and was approved by the Ethics Committees at the participating centers.

**Study design**

Conducted in five centers, of which four were in the United Kingdom and one in Belgium, MOPS was a randomized, double-blind, placebo-controlled, phase I, dose-ranging study of the safety, pharmacodynamics (PDs), and pharmacokinetics (PKs) of monthly oral ibandronate in postmenopausal women. At enrollment, participants were randomized to receive three cycles of monthly oral (every 30 d) placebo or 50, 100, or 150 mg ibandronate (Fig. 1). Because flu-like symptoms have been observed in a minority of patients receiving nitrogen-containing bisphosphonates, the 50-mg arm was split into two arms (n = 18) after the first dosing cycle to separate the effects of dose and first-time treat-ment, with participants continuing on either 50 or 100 mg ibandronate for the remaining cycles (Fig. 1).

Study medication was supplied in monthly blister packages containing three film-coated tablets (50 mg ibandronate or placebo) to the desired dose. All tablets were taken with 240 ml (8 oz) plain water after an overnight fast of at least 6 h. Participants were instructed to maintain an upright posture and continue fasting for at least 60 min after dosing. A standardized breakfast was taken 1 h after drug administration.

**Dose selection**

The ibandronate regimens evaluated in MOPS were selected on the basis of prior clinical experience (26) and clinical trial simulation (27). In BONE, daily and intermittent oral ibandronate regimens of the same cumulative dose (225–240 mg every 3 months) provided comparable (no significant difference) reductions in the risk of new vertebral fractures and changes in BMD and biochemical markers of bone turnover. However, similar to studies of oral daily and weekly bisphosphonates (21, 22), and most likely a result of the extension of the dosing interval, a nominal, yet consistent, advantage was observed in favor of the daily regimen. Thus, in MOPS, it was considered reasonable to explore the efficacy and safety of oral doses beyond the cumulative monthly dose provided by the daily regimen (i.e., >75 mg). Simulated biomarker responses for a range of monthly oral ibandronate regimens supported this conclusion (27).

**Randomization**

A centralized randomization procedure was used to assign participants to the respective treatment arms. However, given the limited experience with the investigational regimens in the study population, a three-step randomization procedure was used to gradually expose small numbers of participants to increasing doses of oral ibandronate. In this way, additional participants were only exposed to higher doses of oral ibandronate after the safety of the lower doses had been established. To this end, a data safety review committee (DSRC) was established from statisticians and clinicians who were not involved in the study. The DSRC was not blinded to treatment, and they monitored adverse events during each step. After each step, the DSRC authorized the exposure of more participants to higher doses of oral ibandronate. In the first step, participants were allocated only to placebo or 50 or 100 mg ibandronate. In the second step, nine participants were allocated to 150 mg ibandronate. In a third step, a further 27 participants were allocated to 150 mg ibandronate.

**Study endpoints**

Safety parameters were: adverse events (including abnormal laboratory findings), and episodes of flu-like symptoms (e.g., fatigue, fever, chills, myalgia, and arthralgia). Serum laboratory safety parameters (hematology, biochemistry) were measured at screening and on d 1, 2, 5, 31, 35, 61, 62, 65, and 91. PTH vs. albumin/calcium was measured at...
d 1 and 91. 25-Hydroxycholecalciferol was measured at screening. Urine safety laboratory parameters were measured at screening and at d 1, 2, 61, 62, and 91. Using a supplied thermometer, participants recorded their body temperature on d 1–5, 31–35, and 61–65.

The primary PD endpoint was relative change (percent) from baseline in concentrations of the C-telopeptide (CTX) of the α-chain of type I collagen, a sensitive biochemical marker of bone resorption, in serum (sCTX) and urine (uCTX) at d 91. An exploratory analysis of the area under the effect curve (AUEC; d 1–91) for relative change (percent × days) in sCTX and uCTX was also performed. sCTX concentrations were measured in blood samples taken between 0800 and 1000 h, after an overnight fast. uCTX concentrations were assessed in the second morning spot urine. Blood and urine samples were taken on d 1 (baseline), 9, 17, 23, 31, 61, 69, 77, 83, and 91. In addition, sCTX was measured on d 5 and 65. Concentrations of sCTX and uCTX (creatinine-corrected) were quantified (centrally) using an automated analyzer (ELECSYS 2010; Roche Diagnostics, Basel, Switzerland) and an ELISA (CrossLaps EIA kit; Roche Diagnostics), respectively.

The primary PK parameter for the estimation of systemic exposure was the area under the concentration time curve (AUC_{0–48}) for ibandronate in serum after the first dose in each group. Secondary PK parameters were: maximum observed plasma concentration (C_{max}), amount of drug excreted in urine (Ae); renal clearance (CLR), calculated as Ae0–48 h divided by AUC_{0–48} h and plasma elimination half-life (t_{1/2}), calculated as ln (2)/k_{el} where k_{el} is the apparent elimination rate determined by linear regression analysis of terminal data points. Blood samples for PK analysis were taken at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 144, and 192 h post dose after the first cycle only and urine samples at 0–6, 6–12, 12–24, 24–48, 48–72, and 72–96 h post dose after the first and third cycles. Concentrations of ibandronate in serum and urine were determined by ELISA and gas chromatography/mass spectrometry, respectively, at a centralized laboratory (MDS Pharma Services, Zurich, Switzerland AG). PK parameters were estimated from model-independent methods (WinNonlin Professional version 3.1 and version 4.0, Pharsight, Mountain View, CA; Excel 97 SR-2, Microsoft, Redmond, WA) using established equations.

**Results**

### Disposition and baseline characteristics

Of the 218 participants screened, 144 were randomized to treatment and received at least one dose of study medication, forming the ITT/safety population (Fig. 1). Of these participants, 130 met the criteria for inclusion in the PP population. Overall, four participants withdrew from the study: three due to adverse events (two in the placebo group and one in the 150-mg ibandronate group), and one (placebo group) because continuous clotting prevented blood samples from being taken.

The baseline characteristics of the ITT/safety population are summarized in Table 1. Treatment arms were well balanced in terms of age, weight, and height. However, in the absence of specific BMD inclusion criteria, some participants were clearly osteoporotic (T-score ≤ −2.5), others osteopenic (T-score ≤ −1 to −2.5), and others normal (T-score ≥ −1), with respect to BMD at the lumbar spine.

### Safety

**Overall safety.** At the studied doses, once-monthly oral ibandronate was well tolerated, with a safety profile similar to placebo (Table 2). Overall, no apparent relationship between adverse events and dose was observed. No differences were observed among study arms in the overall incidence of adverse events, drug-related adverse events, and overall or drug-related adverse events resulting in withdrawal (Table 2). Adverse events were mostly mild to moderate in intensity and typical of the bisphosphonate class. No serious adverse events or deaths were reported (Table 2). No clinically relevant changes in laboratory safety parameters were observed in the active treatment arms relative to placebo. In particular, there were no changes in hepatic or renal function, serum calcium, or PTH. The number of patients experiencing flu-like symptoms was similar across the placebo and active treatment groups and did not increase with increasing ibandronate dose [20, 8, 6, 17, and 16 patients in the placebo; 50, 50/100, 100, and 150 mg ibandronate treatment arms (n = 36, 18, 18, 36, and 36), respectively]. The majority of participants

**TABLE 1.** Mean (range) baseline patient characteristics (ITT/safety population)

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>Age (yr) (mean ± SD)</th>
<th>Weight (kg) (mean ± SD)</th>
<th>Height (cm) (mean ± SD)</th>
<th>Lumbar spine BMD T-score (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (n = 36)</td>
<td>63.9 (55–79)</td>
<td>68.9 (54–105)</td>
<td>161.0 (151–174)</td>
<td>−1.2 (−3.4 to +2.2)</td>
</tr>
<tr>
<td>50 mg (n = 18)</td>
<td>65.7 (61–74)</td>
<td>67.6 (54–86)</td>
<td>161.3 (148–179)</td>
<td>−1.9 (−2.9 to −1.0)</td>
</tr>
<tr>
<td>100 mg (n = 18)</td>
<td>61.7 (55–77)</td>
<td>73.9 (54–108)</td>
<td>161.2 (148–175)</td>
<td>−0.3 (−2.3 to +1.1)</td>
</tr>
<tr>
<td>150 mg (n = 36)</td>
<td>64.1 (56–77)</td>
<td>69.2 (52–101)</td>
<td>162.0 (151–176)</td>
<td>−1.1 (−3.7 to +1.8)</td>
</tr>
<tr>
<td>180 mg (n = 36)</td>
<td>63.3 (55–79)</td>
<td>69.0 (54–100)</td>
<td>161.3 (152–174)</td>
<td>−0.8 (−3.0 to +2.1)</td>
</tr>
</tbody>
</table>

PKs. A one-way ANOVA with factor dose was applied to dose-normalized and log-transformed values of AUC_{0–48}, the primary PK variable. Based on the results of this ANOVA, the systemic exposure at the 100-mg and 150-mg doses was expressed as a ratio to the value obtained at the 50-mg dose. By estimating mean ratios together with 95% confidence intervals (CI) for the two higher doses, and because AUC_{0–48} values were normalized for dose, dose-proportionality of systemic exposure could be evaluated. An identical analysis was performed for the secondary PK variable C_{max}. An exploratory ANOVA with the factors treatment, subject nested in treatment and period was applied to dose-normalized and log-transformed values of Ae (cycles 1 and 3) to estimate intrasubject variability.
reporting flu-like symptoms experienced a single event in isolation.

Upper GI tolerability. The total number of upper GI adverse events occurring within 3 d of treatment, and thus most likely to be a reflection of treatment effect, was comparable across the treatment arms (6, 0, 4, 8, and 9 events in the placebo; 50, 50/100, 100, and 150-mg arms, respectively). Regarding upper GI adverse events occurring at any time during the study, and not just within 3 d of therapy, a slightly higher number of events occurred in the 100- and 150-mg arms (15 events per arm) relative to the other arms (12, 3, and 11 events in the placebo; 50- and 50/100-mg arms, respectively). The majority of these adverse events were mild in intensity.

PDs

Baseline concentrations of sCTX and uCTX did not differ appreciably among groups. The median concentrations in the five groups ranged from 0.42–0.47 mg/ml for sCTX and from 175.7–212.3 µg/mmol for uCTX. The smallest and largest values (all groups) were 0.06 and 1.33 mg/ml, respectively, for sCTX and 22.4 and 546.8 µg/mmol for uCTX.

At the studied doses, once-monthly oral ibandronate was effective in reducing bone turnover, as demonstrated by substantial decreases from baseline in median sCTX and uCTX concentrations at d 91 in the active treatment arms (primary PD endpoint; Table 3); decreases vs. baseline were statistically significant for all dose groups (overall P < 0.0001 by Kruskal-Wallis test). The median reductions from baseline in sCTX and uCTX concentrations were 56.7 and 54.1%, respectively (150-mg arm) and 40.7 and 34.6% (100-mg arm), compared with 12.3 and 5.5% in the placebo arm (PP analysis). The differences between active treatment and placebo in the median reductions from baseline were significant for all but the 50-mg group (P < 0.001 by extended Wilcoxon rank-sum test; Table 3). The results of the ITT analysis were similar to those of the PP analysis. Analysis of the AUEC (d 1–91) for relative change (percent × days) in sCTX and uCTX indicated a dose-response relationship (Fig. 2).

PKs

A summary of the PK parameters after the first oral administration of 50, 100, or 150 mg ibandronate is presented in Table 4.

Ibandronate in serum. The mean serum AUC_{0–∞} associated with the first dose of each of the monthly dosing schedules (primary PK endpoint) is shown in Fig. 3. As expected, systemic exposure in participants receiving 50 mg ibandronate (50- and 50/100-mg arms) was broadly similar. At higher doses (100 mg and 150 mg), however, systemic exposure (AUC_{0–∞}) appeared to increase disproportionately to dose (Fig. 3). Subsequent statistical analysis (ANOVA) of the AUC_{0–∞} gave mean systemic exposure ratios (relative to the 50-mg dose) of 130% (95% CI, 94–180%) and 191% (95% CI, 138–265%) for the 100-mg and 150-mg ibandronate groups, respectively. Given that the CI for the 150-mg-dose group did not contain the equivalence value (100%), the null hypothesis of dose proportionality for the AUC_{0–∞} between all three groups was rejected (P = 0.0006), and it was concluded that the AUC_{0–∞} was not dose-proportional among the three dose groups. ANOVA of the secondary PK parameters, serum C_{max} and Ae, confirmed this finding. A trend toward an increase in t_{1/2} with increasing dose (Table 4) was considered to be a result of low terminal serum concentrations, which approached the limits of assay quantification.

Ibandronate in urine. The overall recovery of ibandronate (Ae) in urine was 0.2–0.4%, with the majority being recovered within the first 6 h post dose (Fig. 4). No differences were observed in Ae for the first and third dosing cycles for each dosing arm. During the first dosing cycle, Ae was slightly higher in the 150-mg arm (0.38%) compared with 100- and 50-mg arms (0.26–0.29%). However, in the third dosing cy-

**TABLE 2.** Overall summary of safety [ITT/safety population; n (%)]

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n = 36)</th>
<th>50 mg (n = 18)</th>
<th>50/100 mg (n = 18)</th>
<th>100 mg (n = 36)</th>
<th>150 mg (n = 36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adverse event</td>
<td>34 (94)</td>
<td>18 (100)</td>
<td>17 (94)</td>
<td>33 (92)</td>
<td>32 (89)</td>
</tr>
<tr>
<td>Any drug-related adverse event*</td>
<td>3 (8)</td>
<td>3 (17)</td>
<td>0</td>
<td>2 (6)</td>
<td>2 (6)</td>
</tr>
<tr>
<td>Any serious adverse event</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Any adverse event leading to withdrawal</td>
<td>2 (6)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 (3)</td>
</tr>
<tr>
<td>Any drug-related adverse event leading to withdrawal*</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Any adverse event leading to death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* Adverse event considered “probably” related to treatment.

**TABLE 3.** Median change (%) from baseline in serum and urine concentrations of CTX at d 91 after monthly treatment with oral ibandronate (PP population)

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>50 mg</th>
<th>50/100 mg</th>
<th>100 mg</th>
<th>150 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>sCTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vs. baseline</td>
<td>-12.3 (-27.7, -3.3)</td>
<td>-22.3 (-39.6, -9.1)</td>
<td>-49.6 (-61.4, -35.4)</td>
<td>-40.7 (-54.0, -25.9)</td>
<td>-56.7 (-70.2, -39.7)</td>
</tr>
<tr>
<td>vs. placebo</td>
<td>-9.0 (-22.2, 5.9)</td>
<td>-32.8 (-45.6, -16.5)</td>
<td>-23.7 (-35.2, -10.4)</td>
<td>-38.6 (-50.0, -26.1)</td>
<td></td>
</tr>
<tr>
<td>uCTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vs. baseline</td>
<td>-5.5 (-25.9, 14.2)</td>
<td>-13.4 (-40.9, 21.3)</td>
<td>-54.8 (-64.2, -32.7)</td>
<td>-34.6 (-58.6, -18.1)</td>
<td>-54.1 (-76.4, -42.6)</td>
</tr>
<tr>
<td>vs. placebo</td>
<td>-5.3 (-26.9, 20.6)</td>
<td>-40.5 (-58.8, -20.9)</td>
<td>-32.0 (-48.9, -14.3)</td>
<td>-51.7 (-65.6, -36.4)</td>
<td></td>
</tr>
</tbody>
</table>

Interquartile limits are given in parentheses. Rows for placebo show differences between medians (95% CI) in the active and placebo groups.

* P < 0.001 for ibandronate vs. placebo, extended Wilcoxon rank-sum test.
cle, Ae was similar among the 150-, 100-, and 50/100-mg arms (0.34, 0.31, and 0.33%, respectively) but was higher than in the 50-mg arm (0.18%). An apparent trend toward a decrease in the CLR of ibandronate with increasing dose was observed. However, this was considered to be the result of the incomplete definition of the AUC of ibandronate in plasma at lower doses.

**Discussion**

Ibandronate is a potent, nitrogen-containing bisphosphonate with proven antifracture efficacy when administered as a daily (vertebral fracture risk reduction, 62%) or intermittent oral regimen (vertebral fracture risk reduction, 50%) with a between-dose interval of more than 2 months to women with postmenopausal osteoporosis (26). Ibandronate has also been shown to provide substantial and comparable increases in BMD at the lumbar spine and hip and decreases in biochemical markers of turnover when administered continuously or less frequently (26, 28). A safety profile similar to that of placebo has also been demonstrated in numerous studies of oral ibandronate, independent of the administration schedule and population characteristics (26, 29–33).

In the current study, we explored the feasibility of administering ibandronate as a once-monthly oral regimen in postmenopausal women. Specifically, we explored the tolerability, PD, and PK of three cycles of monthly oral 50, 50/100, 100, or 150 mg ibandronate, relative to placebo. At the studied doses, once-monthly oral ibandronate was well tolerated, with a safety profile similar to that of placebo. Adverse events were typical of the bisphosphonate class, with no unexpected safety concerns reported. The number of upper GI safety adverse events within 3 d of dosing was comparable across treatment arms. These findings are consistent with prior studies of oral ibandronate in women with and without postmenopausal osteoporosis, in which oral ibandronate was shown to be extremely well tolerated and to have a safety profile similar to that of placebo when administered continuously (2.5 mg), weekly (20 mg), or intermittently (20 mg every other dose for 12 doses every 3 months) (26, 29–33). A favorable tolerability profile has been observed also in patients with metastatic bone disease receiving high individual and cumulative daily doses of ibandronate: in clinical trials, oral daily ibandronate (50 mg) administered for 96 wk was well tolerated, with a safety profile similar to that of placebo (34).

In addition to its good tolerability, once-monthly oral ibandronate was effective in suppressing bone resorption. At d 91, 30 d after the final administration of study medication, substantial and significant relative reductions in median sCTX and uCTX levels were observed. Analysis of the AUEC (d 1–91) for the median relative change in sCTX and uCTX, an integrated PD assessment reflecting the total level of suppression over the analysis period rather than at a single time point, indicated a dose-response relationship for monthly oral ibandronate. Thus, whereas acknowledging the limitations of the MOPS study, these findings, especially those in the higher dose-containing arms (100 and 150 mg), highlight a strong potential for clinically meaningful efficacy with monthly oral ibandronate.

Systemic exposure to ibandronate increased with dose but not in a dose-proportional manner, as shown by calculations of the ratio of dose-normalized AUC values at the higher ibandronate doses relative to the 50-mg value (130% for the 100-mg group and 191% for the 150-mg group). Consequently, a linear association between dose and serum expo-

**TABLE 4. Summary of PK parameters after the first oral administration of monthly oral ibandronate [mean (SD)]**

<table>
<thead>
<tr>
<th>Ibandronate dose</th>
<th>AUC0–91 (ng/h/ml)</th>
<th>Cmax (ng/ml)</th>
<th>t1/2 (h)</th>
<th>CLR (ml/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mg (n = 18)</td>
<td>37.5 (59.2)*</td>
<td>10.7 (21.9)</td>
<td>26.9 (23.2)</td>
<td>76.8 (35.0)</td>
</tr>
<tr>
<td>50/100 mg (n = 18)</td>
<td>38.1 (21.6)</td>
<td>11.7 (7.74)</td>
<td>33.4 (21.9)</td>
<td>69.5 (19.8)</td>
</tr>
<tr>
<td>100 mg (n = 36)</td>
<td>84.1 (53.6)</td>
<td>22.8 (18.9)</td>
<td>58.6 (22.5)</td>
<td>59.4 (18.4)*</td>
</tr>
<tr>
<td>150 mg (n = 36)</td>
<td>208 (185)</td>
<td>49.7 (44.0)</td>
<td>72.0 (15.8)</td>
<td>56.9 (16.6)*</td>
</tr>
</tbody>
</table>

* n = 16.  
* n = 35.  
* n = 33.
The findings of the MOPS study demonstrate that once-monthly oral ibandronate dosing is well tolerated and efficacious in suppressing bone turnover in postmenopausal women. However, given the limitations of the MOPS study, additional evaluation of once-monthly ibandronate dosing is warranted. The MOBILE study is evaluating the efficacy and safety of 100- and 150-mg once-monthly oral ibandronate regimens in postmenopausal women with osteoporosis.

Acknowledgments

Additional investigators and significant contributors to MOPS were Dr. John Lambert (UK), Dr. Christopher Mugglestone (UK), Dr. Graham Mold (UK), Dr. Salvatore Febbraro (UK), and Dr. Jean Fraser (UK).

Received September 3, 2004. Accepted June 14, 2005.

Address all correspondence and requests for reprints to: Professor Jean-Yves Reginster, Unité d’Exploration du Metabolisme de l’Os et du Cartilage, Centre Hospitalier Universitaire Centre Ville, B-4040 Liege, Belgium. E-mail: jyreginster@ulg.ac.be.

This work was supported by F. Hoffmann-La Roche Ltd. (Basel, Switzerland) and GlaxoSmithKline Pharmaceuticals (Collegville, Pennsylvania).

References


Conclusions

The findings of the MOPS study demonstrate that once-monthly oral ibandronate dosing is well tolerated and efficacious in suppressing bone turnover in postmenopausal women. However, given the limitations of the MOPS study, additional evaluation of once-monthly ibandronate dosing is warranted. The MOBILE study is evaluating the efficacy and safety of 100- and 150-mg once-monthly oral ibandronate regimens in postmenopausal women with osteoporosis.

As previously stated, recent studies have shown that therapeutic adherence with osteoporosis medications, including daily and weekly oral bisphosphonates, is suboptimal (12–18). Commonly cited reasons for nonadherence include dosing convenience and/or complexity (38, 39) and side effects (38–40). A convenient once-monthly tablet with a favorable safety and tolerability profile may therefore provide adherence benefits in postmenopausal osteoporosis.

The findings of the MOPS study demonstrate that once-monthly oral ibandronate is well tolerated and efficacious in postmenopausal women. However, given the small number of participants and absence of standardized calcium and vitamin D supplementation in the MOPS study, further evaluation of the once-monthly ibandronate dosing concept is warranted. A large-scale, randomized, double-blind, phase III study [Monthly Oral Ibandronate in Ladies (MOBILE)] will establish the efficacy and safety of 2 yr of treatment with the 100- and 150-mg monthly oral ibandronate regimens in postmenopausal women with osteoporosis. Similar to the studies of oral weekly and daily alendronate (21) and risedronate (22), MOBILE is a noninferiority study, which uses the proven oral daily ibandronate regimen as an active comparator. Vertebral fracture efficacy will be derived if the monthly oral regimens show noninferiority to the oral daily regimen for lumbar spine BMD change (percent) at 1 yr. Positive outcomes from this study will likely provide physicians and

Fig. 4. Mean (SD) urine recoveries (Ae percent) after oral administration of 50, 100, or 150 mg ibandronate to postmenopausal women.
hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808–813

JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.